Very excited to share that our new article is out this week in Science Translational Medicine -- & is featured on the cover! A fitting cap to #ICMI2022! science.org/doi/10.1126/sc… This work from my postdoc in the IrvineLab Koch Institute at MIT Massachusetts Institute of Technology (MIT) introduces an intranasal mucosal vaccine strategy that (1/)

Alum-anchoring #interferons to improve efficacy Koch Institute at MIT Read our summary and interview with the researchers here => ow.ly/3sot50KJ7qA

Thanks ACIR for this nice write up on our recent work leveraging alum anchoring technology to improve the therapeutic index of interferons!

Excited to present data on our IL-12 ANK-101 program Society for Immunotherapy of Cancer Annual Meeting, which highlights the potential of our Anchor Immunotherapy Platform to overcome the limitations of traditional IL-12 to enhance it's therapeutic window to reach more patients bwnews.pr/3Tv2zbX

Really excited to share the work I have done with Haydn Kissick over my PhD! In this work we show that CD8 T cell activation and differentiation in cancer happens in two distinct phases. Tweet-orial below summarizes the main findings we have described. cell.com/immunity/fullt…

Join Koch Institute immune engineers and Ankyra Therapeutics CEO Howard Kaufman on April 4 to hear how they are taking anchored immunotherapy against solid tumors from the lab bench to the cancer clinic. Register: bit.ly/Apr2023-wis

Excited to share that the second paper from my post-doc is out! This was a very fun 4-way collaboration between the Stefani Spranger, White, and Wittrup Lab labs at Massachusetts Institute of Technology (MIT) and the Garcia lab at Stanford University! Koch Institute at MIT MIT Biology SITC Early Career Scientist Committee insight.jci.org/articles/view/…

Exciting news today as we announce our clinical trial collaboration and supply agreement with Merck  to assess ANK-101 in combination with Keytruda® (pembrolizumab) in patients with solid tumors. Read more: ankyratx.com/press-release/…

Having my PhD work actually end up in human clinical trials was only ever a dream. Huge congratulations and thanks to the brilliant Ankyra Therapeutics team for making it a reality!

Excited to share some of my PhD work was pre-printed! Using single-cell sequencing, we took a deep look at a library of CAR signaling architectures to try to identify signal-intrinsic drivers of CAR-T function🧵👇 Michael Birnbaum Koch Institute at MIT MIT Dept of BE biorxiv.org/content/10.110…

we're kicking off another round of hiring at Prox Biosciences (now Arpelos Biosciences) across immunology, antibody engineering, or computational roles. if you know someone looking to join a flat, early-stage startup laser-focused on therapeutic development, DM me!

Thrilled to be part of the TwoStepTx team! Congrats to CEO Caitlyn Miller on spearheading this important vision as we work to develop targeted therapies for solid tumors. More 👇

My dad died from colon cancer in 2020, NFX bio principal Gita Bassman Reinitz lots two parents to cancer, so many people we know are effected by this horrible disease.. businesswire.com/news/home/2024…

We are thrilled to announce our latest investment in TwoStepTx! Read more about why we invested 👇 2048.vc/blog/our-inves… 💡 Enabling targeted delivery to virtually any solid tumor using a unique and modular polyspecific integrin-binding peptide. 👩‍💻 The Founder:

congrats Caitlyn Miller and TwoStepTx on the launch! endpts.com/new-cancer-bio…

Ankyra Therapeutics announces the first visceral tumor patient dosed shorturl.at/nclWG #anchoredimmunotherapy #anchoreddrugconjugates

Held onto all my stock. 📈